• Ahmed K Awad, AbdelgalilMahmoud ShabanMSFaculty of Medicine, Ain-Shams University, Cairo, Egypt., Ahmed R Gonnah, Adel Mouffokes, Unaiza Ahmad, Ayman K Awad, Merihan A Elbadawy, and David Hesketh Roberts.
• Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
• Clin Med (Lond). 2024 May 1; 24 (3): 100211100211.

AbstractPatients with heart failure (HF) and iron deficiency are at increased risk of adverse clinical outcomes. We searched databases for randomised controlled trials that compared IV iron to placebo, in patients with HF with reduced ejection fraction (HFrEF). A total of 7,813 participants, all having HFrEF with 3,998 receiving IV iron therapy, and 3,815 control recipients were included. There was a significant improvement in Kansas City Cardiomyopathy Questionnaire favouring IV iron with MD 7.39, 95% CI [3.55, 11.22], p = 0.0002. Subgroup analysis, based on acute and chronic HF, has displayed a sustained statistical significance. Additionally, a significant increase in the left ventricular ejection fraction % was observed, with MD 3.76, 95% CI [2.32, 5.21], p < 0.00001. A significant improvement in 6-min walk test was noted, with MD 34.87, 95% CI [20.02, 49.72], p < 0.00001. Furthermore, IV iron showed significant improvement in NYHA class, peak VO2, serum ferritin, and haemoglobin levels. Finally, despite the lack of difference in terms of all-cause hospitalisation and HF-related death, IV iron was associated with a significant reduction in HF-related, any cardiovascular reason hospitalisations, and all-cause death; which supports the need for implementation of IV iron as a standard of care in patients with HF and iron deficiency.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

26 keywords...

hide…